Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
α-Synuclein in synaptic function and dysfunction
Abstract α-Synuclein is a neuronal protein that is enriched in presynaptic terminals. Under
physiological conditions, it binds to synaptic vesicle membranes and functions in …
physiological conditions, it binds to synaptic vesicle membranes and functions in …
[HTML][HTML] Trial of prasinezumab in early-stage Parkinson's disease
Background Aggregated α-synuclein plays an important role in the pathogenesis of
Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α …
Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α …
Trial of lixisenatide in early Parkinson's disease
Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …
Perspective on the current state of the LRRK2 field
Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …
developed around the study of this gene and its protein product. Recent studies have begun …
SIRT1 pathway in Parkinson's disease: a faraway snapshot but so close
Silent information regulator (SIRT) has distinctive enzymatic activities and physiological
functions to control cell-cycle progression, gene expression, and DNA stability by targeting …
functions to control cell-cycle progression, gene expression, and DNA stability by targeting …
The pathogenesis of Parkinson's disease
Parkinson's disease is a progressive neurodegenerative condition associated with the
deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease …
deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease …
Neuropathology of incidental Lewy body & prodromal Parkinson's disease
Background Parkinson's disease (PD) is a progressive neurodegenerative disorder
associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there …
associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there …
Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study
The neurodegenerative synucleinopathies, including Parkinson's disease and dementia
with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive …
with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive …
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases
EM Rhea, A Babin, P Thomas, M Omer, R Weaver… - Tissue …, 2024 - Taylor & Francis
Background A number of peptide incretin receptor agonists (IRAs) show promise as
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …